Related Experiment Video
Updated: Jul 4, 2026

Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome
Published on: April 25, 2025
Two cases of burning mouth syndrome treated with olanzapine
Nobuhisa Ueda1, Yuki Kodama, Hikaru Hori
1Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu, Japan. nueda@med.uoeh-u.ac.jp
Abstract:
Two case reports of patients suffering from burning mouth syndrome (BMS), a type of somatoform disorder, who were treated with olanzapine are discussed. One case was a 54-year-old female with BMS who failed to respond to milnacipran treatment. Olanzapine (2.5 mg/day) brought about dramatic improvement in the patient's symptoms, and thereafter milnacipran withdrawal further eliminated her symptoms. The second case was a 51-year-old male with BMS who failed to respond to paroxetine treatment. Olanzapine (2.5 mg/day) was added to the treatment regimen and increased to 5.0 mg/day the following week. The patient noted a reduction in symptoms and continued to live normally thereafter without experiencing severe symptoms. These findings suggest that olanzapine may be useful in the treatment of BMS.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Antipsychotic Drugs: Typical and Atypical Agents
Mania and Antimanic Drugs: Overview
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...